ArticleFrontiers in medicine2026
Association of the
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ATP-sensitive potassium channels regulate insulin release, with the Methods: A case-control sample of 1,415 adults with T2DM were classified as diabetes without retinopathy (DWR; Results: The K allele was more frequent in T2DM than in controls. Although E23K was not associated with overall DR, its effect was stage-specific. In comparisons of PDR with DWR, each additional K allele increased PDR odds, and K/K homozygosity showed a stronger recessive effect. The K/K genotype was notably enriched among DR patients with HbA1c ≤ 7.0%, indicating an elevated risk under good glycemic control, but showed no signal in those with poorer control. It was also overrepresented in PDR. Risk associations were more pronounced in individuals with diabetes duration ≥10 years, and adding genotype information resulted in a small increase in model discrimination beyond age and sex alone (AUC = 0.552-0.598; ΔAUC = 0.046). However, the overall discriminatory performance remained poor, suggesting limited clinical utility of E23K genotyping as an isolated predictive marker. Conclusion: In this Middle Eastern population,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.